Triple-negative breast cancer is more likely to recur than the other two subtypes, with 85% 5-year breast cancer-specific survival for stage I triple-negative tumors vs. 94% to 99% for hormone-receptor-positive and ERBB2-positive types [19]. This evidence concerns the gene ERBB2 and breast cancer.